...
首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms
【24h】

Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms

机译:2258上皮肿瘤中琥珀酸脱氢酶损失的定位

获取原文
获取原文并翻译 | 示例
           

摘要

Losses in the succinate dehydrogenase (SDH) complex characterize 20% to 30% of extra-adrenal paragangliomas and 7% to 8% of gastric GISTs, and rare renal cell carcinomas. This loss is reflected as lack of the normally ubiquitous immunohistochemical expression of the SDH subunit B (SDHB). In paragangliomas, SDHB loss correlates with homozygous loss of any of the SDH subunits, typically by loss-of-function mutations. The occurrence of SDHB losses in other epithelial malignancies is unknown. In this study, we immunohistochemically examined 2258 epithelial, mostly malignant neoplasms including common carcinomas of all sites. Among renal cell carcinomas, SDHB loss was observed in 4 of 711 cases (0.6%), including a patient with an SDHB-deficient GIST. Histologically, the SDHB-negative renal carcinomas varied. There was 1 clear cell carcinoma with a high nuclear grade, 1 papillary carcinoma type 2, 1 unclassified carcinoma with a glandular pattern, and 1 oncocytoid low-grade carcinoma as previously described for SDHB-negative renal carcinoma. None of these patients was known to have paragangliomas or had loss of SDHA expression in the tumor. Three of these patients had metastases at presentation (2 in the adrenal, 1 in the retroperitoneal lymph nodes). There were no cases with SDHB loss among 64 renal oncocytomas. SDHB losses were not seen in other carcinomas, except in 1 prostatic adenocarcinoma (1/57), 1 lymphoepithelial carcinoma of the stomach, and 1 (1/40) seminoma. On the basis of this study, SDHB losses occur in 0.6% of renal cell carcinomas and extremely rarely in other carcinomas. Some of these renal carcinomas may be clinically aggressive. The clinical significance and molecular genetics of these SDHB-negative tumors requires further study.
机译:琥珀酸脱氢酶(SDH)复合物的丢失是肾上腺旁神经节瘤的20%至30%,胃GIST的7%至8%,以及罕见的肾细胞癌。这种损失反映为缺乏SDH亚基B(SDHB)的通常普遍存在的免疫组织化学表达。在神经节瘤中,SDHB丢失与任何SDH亚基的纯合丢失相关,通常是由于功能缺失突变引起的。 SDHB丢失在其他上皮恶性肿瘤中的发生是未知的。在这项研究中,我们免疫组化检查了2258上皮,大部分是恶性肿瘤,包括所有部位的常见癌。在肾细胞癌中,在711例患者中有4例(0.6%)出现了SDHB丢失,包括一名SDHB缺陷型GIST患者。组织学上,SDHB阴性的肾癌多种多样。如先前针对SDHB阴性的肾癌所述,存在1例具有高核级的透明细胞癌,1例2型乳头状癌,1例具有腺体型的未分类癌和1例胞浆状低度癌。这些患者中没有一个在肿瘤中有神经节旁瘤或SDHA表达缺失。这些患者中有3例出现转移(肾上腺2例,腹膜后淋巴结1例)。 64例肾细胞瘤中无SDHB丢失的病例。除1例前列腺腺癌(1/57),1例胃淋巴上皮癌和1例(1/40)精原细胞瘤外,其他癌均未见SDHB丢失。根据这项研究,SDHB丢失发生在0.6%的肾细胞癌中,极少发生在其他癌中。这些肾癌中有些可能在临床上具有侵略性。这些SDHB阴性肿瘤的临床意义和分子遗传学需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号